U.S. markets open in 41 minutes

  • S&P Futures

    3,946.25
    -31.75 (-0.80%)
     

  • Dow Futures

    32,012.00
    -307.00 (-0.95%)
     

  • Nasdaq Futures

    12,791.00
    -63.00 (-0.49%)
     

  • Russell 2000 Futures

    1,711.80
    -20.70 (-1.19%)
     

  • Crude Oil

    67.49
    -2.47 (-3.53%)
     

  • Gold

    1,999.10
    +3.20 (+0.16%)
     

  • Silver

    23.52
    +0.27 (+1.16%)
     

  • EUR/USD

    1.0747
    -0.0090 (-0.83%)
     

  • 10-Yr Bond

    3.3040
    -0.1020 (-2.99%)
     

  • Vix

    24.76
    +2.50 (+11.23%)
     

  • GBP/USD

    1.2212
    -0.0077 (-0.63%)
     

  • USD/JPY

    130.0150
    -0.7740 (-0.59%)
     

  • Bitcoin USD

    28,049.75
    +443.95 (+1.61%)
     

  • CMC Crypto 200

    610.83
    +13.37 (+2.24%)
     

  • FTSE 100

    7,369.16
    -130.44 (-1.74%)
     

  • Nikkei 225

    27,385.25
    -34.36 (-0.13%)
     

CureVac Can Finally Compete With Moderna. It’s an ‘Under-the-Radar mRNA Story.’

4
Angela Palumbo
·2 min read
CureVac Can Finally Compete With Moderna. It’s an ‘Under-the-Radar mRNA Story.’

CureVac is ready to compete in the big leagues with its vaccines, according to a UBS analyst who says the soaring stock has more room to rise. UBS analyst Eliana Merle upgraded the shares (ticker: CVAC) to Buy from Neutral and raised her 12-month target for the stocks price to $18 from $8 on Thursday. Merle listed recent clinical trial data and the biopharmaceutical company’s ability to gain market share as reasons for the upgrade.

Continue reading

Recommended Stories